Pennsylvania | 33-0272839 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
435 Devon Park Drive, Building 100, Wayne, PA 19087 |
Large accelerated filer | o | Accelerated filer | o | |||
Non-accelerated filer | x | Smaller reporting company | x | |||
Emerging growth company | o |
TABLE OF CONTENTS | ||
Page | ||
Item I. | ||
Condensed Consolidated Balance Sheets as of December 31, 2019 and June 30, 2019 | ||
Item 2. | ||
Item 3. | ||
Item 4. | ||
Item 6. |
ESCALON MEDICAL CORP. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) | |||||||
December 31, 2019 | June 30, 2019 | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 234,927 | $ | 409,743 | |||
Restricted cash | 254,556 | 253,135 | |||||
Accounts receivable, net | 1,772,254 | 1,496,105 | |||||
Inventories | 1,963,845 | 1,878,860 | |||||
Other current assets | 201,656 | 223,078 | |||||
Total current assets | 4,427,238 | 4,260,921 | |||||
Property and equipment, net | 90,308 | 67,896 | |||||
Right-of-use assets | 972,244 | — | |||||
Trademarks and trade names | — | 605,006 | |||||
License, net | 131,875 | 141,700 | |||||
Other long term assets | 62,785 | 51,915 | |||||
Total assets | $ | 5,684,450 | $ | 5,127,438 | |||
LIABILITIES AND SHAREHOLDERS’ EQUITY | |||||||
Current liabilities: | |||||||
Line of credit | $ | 201,575 | $ | 201,575 | |||
Current portion of note payable | 3,133 | 3,401 | |||||
Accounts payable | 841,692 | 666,510 | |||||
Accrued expenses | 638,573 | 656,707 | |||||
Related party accrued interest | 112,389 | 112,389 | |||||
Current portion of post-retirement benefits (related party) | — | 101,891 | |||||
Current portion of operating lease liabilities | 251,057 | — | |||||
Deferred revenue | 635,678 | 426,803 | |||||
Liabilities of discontinued operations | 89,720 | 90,933 | |||||
Total current liabilities | 2,773,817 | 2,260,209 | |||||
Note payable, net of current portion | 13,501 | 14,896 | |||||
Operating lease liabilities, net of current portion | 788,863 | — | |||||
Accrued post-retirement benefits, net of current portion (related party) | — | 690,094 | |||||
Total long-term liabilities | 802,364 | 704,990 | |||||
Total liabilities | 3,576,181 | 2,965,199 | |||||
Shareholders' equity: | |||||||
Series A convertible preferred stock, $0.001 par value; 2,000,000 shares authorized; 2,000,000 shares issued and outstanding (liquidation value of $741,980 and $715,968) | 645,000 | 645,000 | |||||
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding | 7,415 | 7,415 | |||||
Additional paid-in capital | 69,702,043 | 69,702,043 | |||||
Accumulated deficit | (68,246,189 | ) | (68,192,219 | ) | |||
Total shareholders’ equity | 2,108,269 | 2,162,239 | |||||
Total liabilities and shareholders’ equity | $ | 5,684,450 | $ | 5,127,438 |
ESCALON MEDICAL CORP. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) | |||||||||||||||
For the Three Months Ended December 31, | For the Six Months Ended December 31, | ||||||||||||||
2019 | 2018 | 2019 | 2018 | ||||||||||||
Net revenues: | |||||||||||||||
Products | $ | 2,497,107 | $ | 2,197,050 | $ | 4,549,286 | $ | 4,219,433 | |||||||
Service plans | 242,786 | 221,830 | 478,595 | 457,830 | |||||||||||
Revenues, net | 2,739,893 | 2,418,880 | 5,027,881 | 4,677,263 | |||||||||||
Costs and expenses: | |||||||||||||||
Cost of goods sold | 1,452,179 | 1,280,173 | 2,628,849 | 2,483,306 | |||||||||||
Marketing, general and administrative | 1,093,930 | 1,138,916 | 2,093,357 | 2,141,153 | |||||||||||
Research and development | 261,759 | 226,338 | 507,397 | 322,746 | |||||||||||
Intangible assets impairment | 605,006 | — | 605,006 | — | |||||||||||
Total costs and expenses | 3,412,874 | 2,645,427 | 5,834,609 | 4,947,205 | |||||||||||
Loss from operations | (672,981 | ) | (226,547 | ) | (806,728 | ) | (269,942 | ) | |||||||
Other income (expense) | |||||||||||||||
Other income | — | 11,122 | 758,021 | 11,122 | |||||||||||
Interest income | 1,757 | 864 | 2,840 | 3,374 | |||||||||||
Interest expense | (4,119 | ) | (3,422 | ) | (8,103 | ) | (10,273 | ) | |||||||
Total other expense (income), net | (2,362 | ) | 8,564 | 752,758 | 4,223 | ||||||||||
Net loss | (675,343 | ) | (217,983 | ) | (53,970 | ) | (265,719 | ) | |||||||
Undeclared dividends on preferred stocks | 13,006 | 13,006 | 26,012 | 26,011 | |||||||||||
Net loss applicable to common shareholders | $ | (688,349 | ) | $ | (230,989 | ) | $ | (79,982 | ) | $ | (291,730 | ) | |||
Net loss per share | |||||||||||||||
Basic loss per share | $ | (0.09 | ) | $ | (0.03 | ) | $ | (0.01 | ) | $ | (0.04 | ) | |||
Diluted loss per share | $ | (0.09 | ) | $ | (0.03 | ) | $ | (0.01 | ) | $ | (0.04 | ) | |||
Weighted average shares—basic | 7,415,329 | 7,415,329 | 7,415,329 | 7,415,329 | |||||||||||
Weighted average shares—diluted | 7,415,329 | 7,415,329 | 7,415,329 | 7,415,329 |
ESCALON MEDICAL CORP. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY FOR THE THREE AND SIX MONTHS ENDED DECEMBER 31, 2019 AND DECEMBER 31, 2018 (UNAUDITED) | ||||||||||||||||||||||||||||
Series A Convertible Preferred Stock | Common Stock | Additional Paid-in Capital | Accumulated Deficit | Total Shareholders’ Equity | ||||||||||||||||||||||||
Shares | Amount | Shares | Amount | |||||||||||||||||||||||||
Balance at June 30, 2019 | 2,000,000 | $ | 645,000 | 7,415,329 | $ | 7,415 | $ | 69,702,043 | $ | (68,192,219 | ) | $ | 2,162,239 | |||||||||||||||
Net income | — | — | — | — | — | — | 621,373 | 621,373 | ||||||||||||||||||||
Balance at September 30, 2019 | 2,000,000 | 645,000 | 7,415,329 | 7,415 | — | 69,702,043 | — | (67,570,846 | ) | 2,783,612 | ||||||||||||||||||
Net loss | — | — | — | — | — | (675,343 | ) | (675,343 | ) | |||||||||||||||||||
Balance at December 31, 2019 | 2,000,000 | $ | 645,000 | 7,415,329 | $ | 7,415 | $ | 69,702,043 | $ | (68,246,189 | ) | $ | 2,108,269 |
Series A Convertible Preferred Stock | Common Stock | Additional Paid-in Capital | Accumulated Deficit | Total Shareholders’ Equity | ||||||||||||||||||||||||||
Shares | Amount | Shares | Amount | |||||||||||||||||||||||||||
Balance at June 30, 2018 | 2,000,000 | $ | 645,000 | 7,415,329 | $ | 7,415 | $ | 69,702,043 | $ | (67,942,203 | ) | $ | 2,412,255 | |||||||||||||||||
Net loss | — | — | — | — | — | (47,736 | ) | (47,736 | ) | |||||||||||||||||||||
Balance at September 30, 2018 | 2,000,000 | — | 645,000 | 7,415,329 | 7,415 | — | 69,702,043 | — | (67,989,939 | ) | — | 2,364,519 | ||||||||||||||||||
Net loss | — | — | — | — | — | (217,983 | ) | (217,983 | ) | |||||||||||||||||||||
Balance at December 31, 2018 | 2,000,000 | $ | 645,000 | 7,415,329 | $ | 7,415 | $ | 69,702,043 | $ | (68,207,922 | ) | $ | 2,146,536 |
ESCALON MEDICAL CORP. AND SUBSIDIARIES | |||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||
(UNAUDITED) | |||||||
For the Six Months Ended December 31, | |||||||
2019 | 2018 | ||||||
Cash Flows from Operating Activities: | |||||||
Net loss | $ | (53,970 | ) | $ | (265,719 | ) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
Depreciation and amortization | 23,474 | 24,927 | |||||
Non cash lease expense | 165,633 | — | |||||
Intangible assets impairment | 605,006 | — | |||||
Non cash post-retirement benefits adjustment | (758,021 | ) | — | ||||
Change in operating assets and liabilities: | |||||||
Accounts receivable | (276,149 | ) | 87,364 | ||||
Inventories | (84,985 | ) | (145,257 | ) | |||
Other current assets | 21,423 | 12,020 | |||||
Other long-term assets | (10,870 | ) | — | ||||
Accounts payable | 175,182 | 211,335 | |||||
Accrued expenses | 52,455 | (138,004 | ) | ||||
Accrued post-retirement benefits (related party) | (33,964 | ) | (19,167 | ) | |||
Change in operating lease liability | (168,546 | ) | — | ||||
Deferred revenue | 208,875 | (15,164 | ) | ||||
Liabilities of discontinued operations | (1,213 | ) | (1,029 | ) | |||
Net cash used in operating activities | (135,670 | ) | (248,694 | ) | |||
Cash Flows from Investing Activities: | |||||||
Purchase of equipment | (36,061 | ) | (6,506 | ) | |||
Net cash used in investing activities | (36,061 | ) | (6,506 | ) | |||
Cash Flows from Financing Activities: | |||||||
Repayment of note payable | (1,664 | ) | (1,287 | ) | |||
Proceeds from line of credit | — | 36,575 | |||||
Net cash (used in) provided by financing activities | (1,664 | ) | 35,288 | ||||
Net decrease in cash, cash equivalents and restricted cash | (173,395 | ) | (219,912 | ) | |||
Cash, cash equivalents and restricted cash, beginning of year | 662,878 | 1,124,002 | |||||
Cash, cash equivalents and restricted cash, end of year | $ | 489,483 | $ | 904,090 | |||
Cash, cash equivalents and restricted cash consist of the following: | |||||||
End of period | |||||||
Cash and cash equivalents | $ | 234,927 | $ | 652,518 | |||
Restricted cash | 254,556 | 251,572 | |||||
$ | 489,483 | $ | 904,090 | ||||
Beginning of period | |||||||
Cash and cash equivalents | $ | 409,743 | $ | 874,002 | |||
Restricted cash | 253,135 | 250,000 | |||||
$ | 662,878 | $ | 1,124,002 | ||||
Supplemental Schedule of Cash Flow Information: | |||||||
Interest paid | $ | 8,775 | $ | 39,070 |
Non Cash Finance Activities | |||||||
Record right-of-use assets per ASC 842, net of deferred rent reclassification | $ | 1,137,878 | $ | — | |||
Record lease liability per ASC 842 | $ | 1,208,466 | $ | — |
• | Unsatisfied Performance Obligations - all performance obligations relate to contracts with a duration of less than one year, the Company has elected to apply the optional exemption provided in ASC 606 and therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. |
• | Contract Costs - all incremental customer contract acquisition costs are expensed as they are incurred as the amortization period of the asset that the Company otherwise would have recognized is one year or less in duration. |
• | Significant Financing Component - the Company does not adjust the promised amount of consideration for the effects of a significant financing component as the Company expects, at contract inception, that the period between when the entity transfers a promised good or service to a customer and when the customer pays for that good or service will be one year or less. |
• | Sales Tax Exclusion from the Transaction Price - the Company excludes from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from the customer. |
• | Shipping and Handling Activities - the Company elected to account for shipping and handling activities as a fulfillment cost rather than as a separate performance obligation. |
• | Portfolio Approach - the Company applied the Portfolio Approach to contract reviews within its identified revenue streams that have similar characteristics and the Company believes this approach would not differ materially than if applying Topic 606 to each individual contract. |
(in thousands) | Three Months Ended December 31, | Six Months Ended December 31, | ||||||||||||||
2019 | 2018 | 2019 | 2018 | |||||||||||||
Beginning of Period | $ | 426 | $ | 498 | $ | 427 | $ | 481 | ||||||||
Additions | 452 | 207 | 687 | 459 | ||||||||||||
Revenue Recognized | 242 | 239 | 478 | 474 | ||||||||||||
End of Period | 636 | $ | 466 | $ | 636 | $ | 466 |
For the Three Months Ended December 31, | For the Six Months Ended December 31, | |||||||||||||||
2019 | 2018 | 2019 | 2018 | |||||||||||||
Numerator: | ||||||||||||||||
Numerator for basic loss per share: | ||||||||||||||||
Net loss | $ | (675,343 | ) | $ | (217,983 | ) | $ | (53,970 | ) | $ | (265,719 | ) | ||||
Undeclared dividends on preferred stock | 13,006 | 13,006 | 26,012 | 26,011 | ||||||||||||
Net loss applicable to common shareholders | $ | (688,349 | ) | $ | (230,989 | ) | $ | (79,982 | ) | $ | (291,730 | ) | ||||
Numerator for diluted earnings per share: | ||||||||||||||||
Net loss applicable to common shareholders | $ | (688,349 | ) | $ | (230,989 | ) | $ | (79,982 | ) | $ | (291,730 | ) | ||||
Undeclared dividends on preferred stock | 13,006 | 13,006 | 26,012 | 26,011 | ||||||||||||
Net loss | $ | (675,343 | ) | $ | (217,983 | ) | $ | (53,970 | ) | $ | (265,719 | ) | ||||
Denominator: | ||||||||||||||||
Denominator for basic loss per share - weighted average shares outstanding | 7,415,329 | 7,415,329 | 7,415,329 | 7,415,329 | ||||||||||||
Weighted average preferred stock converted to common stock | — | — | — | |||||||||||||
Denominator for diluted loss per share - weighted average and assumed conversion | 7,415,329 | 7,415,329 | 7,415,329 | — | 7,415,329 | |||||||||||
Net loss per share: | ||||||||||||||||
Basic net loss per share | $ | (0.09 | ) | $ | (0.03 | ) | $ | (0.01 | ) | $ | (0.04 | ) | ||||
Diluted net loss per share | $ | (0.09 | ) | $ | (0.03 | ) | $ | (0.01 | ) | $ | (0.04 | ) |
For the Three Months Ended December 31, | For the Six Months Ended December 31, | ||||||||||
2019 | 2018 | 2019 | 2018 | ||||||||
Stock options | 213,000 | 213,000 | 213,000 | 213,000 | |||||||
Convertible preferred stock | 4,946,531 | 4,602,532 | 4,946,531 | 4,602,532 | |||||||
Total potential dilutive securities not included in income per share | 5,159,531 | 4,815,532 | 5,159,531 | 4,815,532 |
December 31, | June 30, | ||||||
(in thousands) | 2019 | 2019 | |||||
Inventories, net: | |||||||
Raw Material | $ | 887 | $ | 875 | |||
Work-In-Process | 183 | 225 | |||||
Finished Goods | 894 | 779 | |||||
Total | $ | 1,964 | $ | 1,879 |
December 31, | June 30, | ||||||
2019 | 2019 | ||||||
Assets | |||||||
Total assets | $ | — | $ | — | |||
Liabilities | |||||||
Accrued lease termination costs | 90 | 91 | |||||
Total liabilities | 90 | 91 | |||||
Net liabilities of discontinued operations | $ | (90 | ) | $ | (91 | ) |
( in thousands) | For the Three Months Ended December 31, | For the Six Months Ended December 31, | |||||||||||||||||||||||||
2019 | 2018 | 2019 | 2018 | ||||||||||||||||||||||||
Domestic | $ | 1,590 | 58.0 | % | $ | 1,441 | 59.6 | % | $ | 3,056 | 60.8 | % | $ | 2,913 | 62.3 | % | |||||||||||
Foreign | 1,150 | 42.0 | % | 978 | 40.4 | % | 1,972 | 39.2 | % | 1,764 | 37.7 | % | |||||||||||||||
Total | $ | 2,740 | 100.0 | % | $ | 2,419 | 100.0 | % | $ | 5,028 | 100.0 | % | $ | 4,677 | 100.0 | % |
Three Months Ended | Six Months Ended | |||||||
December 31, 2019 | December 31, 2019 | |||||||
Operating lease costs: | ||||||||
Fixed | 104,449 | 208,898 | ||||||
Total: | $ | 104,449 | $ | 208,898 |
Three Months Ended | Six Months Ended | |||||||
December 31, 2019 | December 31, 2019 | |||||||
Cash paid for amounts included in the measurement of lease liabilities | ||||||||
Operating cash flows for operating leases | 101,053 | 200,629 | ||||||
Total | $ | 101,053 | $ | 200,629 |
December 31, | ||||||
Leases (operating) | Classification on the Balance Sheet | 2019 | ||||
Assets | ||||||
Operating lease ROU assets | Right-of-use asset | $ | 972,244 | |||
Liabilities | ||||||
Current | Current portion of operating lease liabilities | 251,057 | ||||
Non-current | Operating lease liabilities | 788,863 |
Operating | ||||
2020 (excluding the six months ending December 31, 2019) | $ | 159,805 | ||
2021 | 276,894 | |||
2022 | 260,628 | |||
2023 | 189,848 | |||
2024 | 189,790 | |||
Thereafter | 96,830 | |||
Total lease payments | 1,173,795 | |||
Less interest | 133,875 | |||
Present value of lease liabilities | $ | 1,039,920 |
December 31, | |||
2019 | |||
Weighted-average remaining lease terms (years) | |||
Operating leases | 4.36 | ||
Weighted-average discount rate | |||
Operating leases | 5.65 | % |
Operating | ||||
2019 | $ | 356,414 | ||
2020 | 272,881 | |||
2021 | 256,311 | |||
2022 | 188,755 | |||
2023 | 189,790 | |||
Thereafter | 96,830 | |||
Total lease payments | $ | 1,360,981 |
• | Consolidated net revenue increased approximately $351,000 or 7.5%, to $5,028,000 during the six-month period ended December 31, 2019 as compared to the same period of last fiscal year. The increase in net revenue is attributed to an increase in sales of Trek products of $383,000 mainly due to back ordered items shipped in the six-month period |
• | Consolidated cost of goods sold totaled approximately $2,629,000, or 52.3%, of total revenue for the six-month period ended December 31, 2019, as compared to $2,483,000, or 53.1%, of total revenue of the same period of last fiscal year. The decrease of 0.8% in cost of goods sold as a percentage of total revenue is mainly due to changes in product sales mix and improved pricing. |
• | Consolidated marketing, general and administrative expenses decreased $47,000, or 2.2%, to $2,094,000 for the six-month period ended December 31, 2019, as compared to the same period of last fiscal year. The decrease is mainly due to decreased legal expense, accounting and consulting expense. |
• | Consolidated research and development expenses increased $184,000 or 57.0%, to $507,000 for the six-month period ended December 31, 2019, as compared to the same period of last fiscal year. Research and development expenses were primarily expenses associated with the introduction of new or enhanced products. The increase in research and development expense is mainly due to expense for AXIS software development work and ultrasound certification costs incurred during the six-month period ended December 31, 2019. |
• | The increase of operating loss is also due to the loss from an intangible assets impairment of $605,000 in the six-month period ended December 31, 2019 as compared to the same period of the last fiscal year. |
For the Three Months Ended December 31, | For the Six Months Ended December 31, | ||||||||||||||||||||
2019 | 2018 | % Change | 2019 | 2018 | % Change | ||||||||||||||||
Net Revenue: | |||||||||||||||||||||
Products | $ | 2,497 | $ | 2,197 | 13.7 | % | $ | 4,549 | $ | 4,219 | 7.8 | % | |||||||||
Service plans | 243 | 222 | 9.5 | % | 479 | 458 | 4.6 | % | |||||||||||||
Total | $ | 2,740 | $ | 2,419 | 13.3 | % | $ | 5,028 | $ | 4,677 | 7.5 | % |
For the Three Months Ended December 31, | For the Six Months Ended December 31, | ||||||||||||||||||||||||||
2019 | 2018 | 2019 | 2018 | ||||||||||||||||||||||||
Domestic | $ | 1,590 | 58.0 | % | $ | 1,441 | 59.6 | % | $ | 3,056 | 60.8 | % | $ | 2,913 | 62.3 | % | |||||||||||
Foreign | 1,150 | 42.0 | % | 978 | 40.4 | % | 1,972 | 39.2 | % | 1,764 | 37.7 | % | |||||||||||||||
Total | $ | 2,740 | 100.0 | % | $ | 2,419 | 100.0 | % | $ | 5,028 | 100.0 | % | $ | 4,677 | 100.0 | % |
For the Three Months Ended December 31, | For the Six Months Ended December 31, | ||||||||||||||||||||||||||
2019 | % | 2018 | % | 2019 | % | 2018 | % | ||||||||||||||||||||
Cost of Goods Sold: | |||||||||||||||||||||||||||
$ | 1,452 | 53.0 | % | $ | 1,280 | 52.9 | % | $ | 2,629 | 52.3 | % | $ | 2,483 | 53.1 | % | ||||||||||||
Total | $ | 1,452 | 53.0 | % | $ | 1,280 | 52.9 | % | $ | 2,629 | 52.3 | % | $ | 2,483 | 53.1 | % |
For the Three Months Ended December 31, | For the Six Months Ended December 31, | ||||||||||||||||||||
2019 | 2018 | % Change | 2019 | 2018 | % Change | ||||||||||||||||
Marketing, General and Administrative: | |||||||||||||||||||||
$ | 1,094 | $ | 1,139 | (4.0 | )% | $ | 2,094 | $ | 2,141 | (2.2 | )% | ||||||||||
Total | $ | 1,094 | $ | 1,139 | (4.0 | )% | $ | 2,094 | $ | 2,141 | (2.2 | )% |
For the Three Months Ended December 31, | For the Six Months Ended December 31, | ||||||||||||||||||||
2019 | 2018 | % Change | 2019 | 2018 | % Change | ||||||||||||||||
Research and Development: | |||||||||||||||||||||
$ | 262 | $ | 226 | 15.9 | % | $ | 507 | $ | 323 | 57.0 | % | ||||||||||
Total | $ | 262 | $ | 226 | 15.9 | % | $ | 507 | $ | 323 | 57.0 | % |
December 31, | June 30, | |||
2019 | 2019 | |||
Current Ratio: | ||||
Current assets | $4,427 | $4,261 | ||
Less: Current liabilities | 2,774 | 2,260 | ||
Working capital | $1,653 | $2,001 | ||
Current ratio | 1.60 to 1 | 1.89 to 1 | ||
Debt to Total Capital Ratio: | ||||
Line of credit, note payable and lease liabilities | $1,258 | $220 | ||
Total debt | 1,258 | 220 | ||
Total equity | 2,108 | 2,162 | ||
Total capital | $3,366 | $2,382 | ||
Total debt to total capital | 37.4% | 9.2% |
Escalon Medical Corp. | ||||
(Registrant) | ||||
Date: February 14, 2020 | By: | /s/ Richard J. DePiano, Jr. | ||
Richard J. DePiano, Jr. | ||||
Chief Executive Officer | ||||
Date: February 14, 2020 | By: | /s/ Mark Wallace | ||
Mark Wallace | ||||
Chief Operating Officer and Principal Accounting & Financial Officer |
1. | I have reviewed this annual report on Form 10-Q of Escalon Medical Corp.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
/s/ Richard J. DePiano Jr. | |
Richard J. DePiano Jr. | |
Chief Executive Officer | |
Date: February 14, 2020 |
1. | I have reviewed this annual report on Form 10-Q of Escalon Medical Corp.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
/s/ Mark Wallace | |
Mark Wallace | |
Date: February 14, 2020 |
1. | The Quarterly Report of Escalon Medical Corp. on Form 10Q for the quarterly period ended December 31, 2019 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/s/ Richard J. DePiano Jr. | |
Richard J. DePiano Jr. | |
Chief Executive Officer |
1. | The Quarterly Report of Escalon Medical Corp. on Form 10-Q for the quarterly period ended December 31, 2019 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/s/ Mark Wallace | |
Mark Wallace | |
Chief Operating Officer and Principal Accounting & Financial Officer |
Significant Accounting Policies deferred revenue (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | |||||
---|---|---|---|---|---|---|---|
Dec. 31, 2019 |
Dec. 31, 2018 |
Sep. 30, 2018 |
Dec. 31, 2019 |
Sep. 30, 2019 |
Jun. 30, 2019 |
Jun. 30, 2018 |
|
Revenue Recognition and Deferred Revenue [Abstract] | |||||||
Deferred Revenue | $ 636 | $ 466 | $ 498 | $ 636 | $ 426 | $ 427 | $ 481 |
Deferred Revenue, Additions | 452 | 207 | 459 | 687 | |||
Deferred Revenue, Revenue Recognized | $ 242 | $ 239 | $ 474 | $ 478 |
Significant Accounting Policies (Accounts Receivable) (Details) $ in Thousands |
Sep. 30, 2019
USD ($)
|
---|---|
Accounting Policies [Abstract] | |
Allowance for Doubtful Accounts Receivable | $ 111 |
Leases (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2019
USD ($)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases 842 [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Future Minimum Rental Payments for Operating Leases |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lease, Cost [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Lease Payments | $ 101,053 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases of Lessee Disclosure [Text Block] |
The Company adopted ASC Topic 842-Leases as of July 1, 2019, using the cumulative effective adjustment method wherein the Company applied the new lease standard at adoption date. Accordingly, all periods prior to July 1, 2019 were presented in accordance with the previous ASC Topic 840, Leases, and no retrospective adjustments were made to the comparative periods presented. Adoption of ASC 842 resulted in an increase to total assets and liabilities due to the recording of operating lease ROU and operating lease liabilities of approximately $1,138,000 and $1,208,000 respectively, as of July 1, 2019. The adoption did not materially impact the Company's unaudited condensed consolidated statements of operations or cash flows. The Company determines if a contract contains a lease at inception. US GAAP requires that the Company's leases be evaluated and classified as operating or finance leases for financial reporting purposes. The classification evaluation begins at the commencement date and the lease term used in the evaluation includes the non-cancellable period for which the Company has the right to use the underlying asset, together with renewal option periods when the exercise of the renewal option is reasonable certain and failure to exercise such option which result in an economic penalty. The Company has operating leases for manufacturing, research and corporate office facilities and certain equipment. Leases with an initial term of 12 months or less are not recorded in the balance sheet. The Company has elected the practical expedient to account for each separate lease component of a contract and its associated non-lease components as a single lease component, thus causing all fixed payments to be capitalized. The Company also elected the package of practical expedients permitted within the new standard, which among other things, allows the Company to carry forward historical lease classification. Variable lease payment amounts that cannot be determined at the commencement of the lease such as increases in lease payments based on changes in index rates or usage, are not included in the ROU assets or liabilities. These are expensed as incurred and recorded as variable lease expense. ROU assets represent the Company's right to use an underlying asset during the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at commencement date based on the net present value of fixed lease payments over the lease term. The Company's lease term includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. As the Company's operating leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the comment date in determining the present value of future lease payments. The components of lease costs included in cost of goods sold and marketing, general and administrative costs were as follows:
Supplemental cash flow information was as follows:
Leases recorded on the balance sheet consist of the following:
The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the unaudited condensed consolidated balance sheets as of December 31, 2019: The aggregate future lease payments for operating leases as of December 31, 2019 were as follows:
Average lease terms and discount rates were as follows:
As of December 31, 2019, the Company has an additional operating lease for its Pennsylvania headquarters location that has not yet commenced with a present value of approximately $285,000. The relocation date is January 1, 2020. The operating lease commenced in the third quarter of fiscal year 2020 with a lease term of 5 years. Disclosures related to periods prior to adoption of ASU 2016-02 The Company adopted ASU 2016-02 using a modified retrospective adoption method at July 1, 2019 as noted in note 3. As required, the following disclosure is provided for periods prior to adoption. Minimum operating lease commitments as of June 30, 2019 that have initial or remaining lease terms in excess of one year are as follows:
The rent expense for the three months ended December 31, 2018 was approximately $114,000. |
Consolidated Balance Sheets (Parenthetical) - $ / shares |
Dec. 31, 2019 |
Jun. 30, 2019 |
---|---|---|
Statement of Financial Position [Abstract] | ||
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 2,000,000 | 2,000,000 |
Preferred Stock, Shares Issued | 2,000,000 | 2,000,000 |
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 35,000,000 | 35,000,000 |
Common stock, shares issued | 7,415,329 | 7,415,329 |
Common stock, shares outstanding | 7,415,329 | 7,415,329 |
Organization and Description of Business |
6 Months Ended |
---|---|
Dec. 31, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Description of Business and Business Conditions | Escalon Medical Corp. ("Escalon" or "Company") is a Pennsylvania corporation initially incorporated in California in 1987, and reincorporated in Pennsylvania in November 2001. Within this document, the “Company” collectively shall mean Escalon, which includes its division called "Trek" and its wholly owned subsidiaries: Sonomed, Inc. (“Sonomed”), Escalon Digital Solutions, Inc. (“EMI”), Escalon Holdings, Inc. (“EHI”), Escalon IP Holdings, Inc., and Sonomed IP Holdings, Inc. The Company operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the United States Food and Drug Administration (the “FDA”). The FDA and other government authorities require extensive testing of new products prior to sale and have jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing. The unaudited condensed consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, and reflect all adjustments (consisting of only normal and recurring adjustments) which are, in the opinion of management, necessary to present fairly the unaudited condensed consolidated financial information required herein. Certain information and note disclosures normally included in financial statement prepared in accordance with accounting principles generally accepted in the United Statements of America ("US GAAP") have been condensed or omitted pursuant to such rules and regulations. While management believes that the disclosures are adequate to make the information presented not misleading, it is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K filed with the Security and Exchange Commission for the fiscal year ended June 30, 2019. The results of operations for the six-month period ended December 31, 2019 are not necessarily indicative of the results to be expected for the full year. The Company’s common stock trades on the OTCQB Market under the symbol “ESMC.” |
Discontinued operation (Details) - USD ($) $ in Thousands |
Jan. 18, 2012 |
Dec. 31, 2019 |
Jun. 30, 2019 |
Jun. 30, 2015 |
---|---|---|---|---|
BH Holdings, S.A.S [Member] | ||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Disposal Group, Including Discontinued Operation, Assets | $ 0 | $ 0 | ||
Disposal Group, Including Discontinued Operation, Other Liabilities, Current | 90 | 91 | $ 86 | |
Disposal Group, Including Discontinued Operation, Liabilities | 90 | 91 | ||
Assets (Liabilities) of Disposal Group, Including Discontinued Operation, Net | $ (90) | $ (91) | ||
BH Holdings, S.A.S [Member] | ||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Bankruptcy Proceedings, Operating Period During Liquidation | 3 months |
Revenue from contracts with customers (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | |||||
---|---|---|---|---|---|---|---|
Dec. 31, 2019 |
Dec. 31, 2018 |
Sep. 30, 2018 |
Dec. 31, 2019 |
Sep. 30, 2019 |
Jun. 30, 2019 |
Jun. 30, 2018 |
|
Movement in Deferred Revenue [Roll Forward] | |||||||
Deferred Revenue | $ 636 | $ 466 | $ 498 | $ 636 | $ 426 | $ 427 | $ 481 |
Deferred Revenue, Additions | 452 | 207 | 459 | 687 | |||
Deferred Revenue, Revenue Recognized | $ 242 | $ 239 | $ 474 | $ 478 |
Significant Accounting Policies (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] |
The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Inventory, Current [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deferred Revenue, by Arrangement, Disclosure [Table Text Block] |
|
Concentration of credit risk (Notes) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk Disclosure [Text Block] | Concentration of Credit Risk Credit Risk Financial Instruments, which potentially subject the Company to concentration of credit risk, consist principally of cash and cash equivalents, restricted cash and trade receivables. Concentration of credit risk with respect to trade receivables is generally diversified due to the large number of entities comprising the Company's customer base and their dispersion across geographic areas principally within the United States and international. The Company routinely address the financial strength of its customer and, as a consequence, believes that its receivable credit risk exposure is limited. The Company does not require customers to post collateral. Major Customer One customer accounted for more than 10% of net sales during the three months and six-month periods ended December 31, 2019. No customer accounted for more than 10% of net sales during the three months and six-month periods ended December 31, 2018. As of December 31, 2019 the Company had one customer that represents approximately 28% of the total accounts receivable balance. As of June 30, 2019 the Company had no customer that represents more than 10% of the total accounts receivable balance. Major Supplier The Company's largest supplier accounted for 38% of the total purchase for the three-month period ended December 31, 2019. The Company's three largest suppliers accounted for 39%, 12% and 10% of the total purchase for the three-month period ended December 31, 2018. The Company's two largest suppliers accounted for 32% and 11% of the total purchase for the six-month period ended December 31, 2019. The Company's two largest suppliers accounted for of total purchases for more than 33% and 10% of total purchase for the six-month period ended December 31, 2018. Foreign Sales Domestic and international sales from continuing operations are as follows:
|
SO-V11XT\]/B"WON/P#4$L#!!0 ( $F 3E ?X@D2T@$ +H$ 9
M>&PO=V]R:W-H965T 6\F]K-#N*+\-F+WN#\7^P%%G3SRK>%_1_H/4$L#!!0 (
M $F 3E ([IF5*0( %(& 9 >&PO=V]R:W-H965T 5I%;RI+IN^!U]MTO(JRZ^BG\OBIKZ.
M3HO--LF#(]/77*?PFMUCX-<-X/Q%72R^Q/ $7ICH0U-7=9(OX4T]C[W)ZQ2O
M2/8UQ6-+(L'&$'GZWBO8^S'=%F6-6[JHDSH$^[^']_>TR*MBG2T)&U\FZR1?
MI+C7M*ZB0?3YXBS:>[Z_DRZT?_Q3D\./H^X?=:5)5<$;7@0_)]5U!+"*%OA'
M^M 6J4)0U2-BU4J,:8'FQUOT"=#894L@K
MJA)@-U$%"R?3;Z[LA I]YJ^Q^>L #TIV\1NF^.2%5@'>I9Q5O1XF5:91?7!3QGS=O??9:<'Z;L6L0FC&G"<-7F&1!,*^^E.!;)4[\/_J>
M;_/WFQ;WD;]_8_%N6R#=%$BC0/I&X/"NQRW,QW=%V.I0-9@FCI,E)0Y='.55
M=IG8>QXOY1]\&O?OPC2RL^2"SE]MO( :T8&WLKOQ,]3Z%[8$"FH7MG=^;Z8Y
MFP*'_?R$V/*.B[]02P,$% @ 28!.4/2F(Z+= 0 @4 !D !X;"]W
M;W)K
D;V'@&Q$
M?)B=7R3QBB0>@G@C,F$2A^FFZPJC\#.=U*N3?M0AVV?APVSO%:_>(0=9NPY4
M02&&SG7_RKLT^3UQ[_@_?/HA?E!9MYT*KD*;;G!OMA)"@TDEO#,'VYA/:3$8
M5-HN4[.64VM.AA;]_.O@Y>O+_P%02P,$% @ 28!.4+Y@PQVZ 0 W0,
M !D !X;"]W;W)K
'*P 3><
M]M!9&P#Y%C=XE3T^]#E0T(7HKM%W^;IS$.PPO60V_T[U.U!+ P04 " !)
M@$Y0?RYKHZ$" V"0 &0 'AL+W=OLR/_D\N_SF^UNO-N7O9YR:LF%Y53\\/*
M?<:+E'0&'?%WSJ_-Z-III;P+\;.]^;I?N:C-B!=\)UL7F?KYX"^\*%I/*H]_
M!Z?N+69K.+[^])YTXI68]ZSA+Z+X)]_+T\J-7&?/#]FED#_$]0\^" I<9U#_
MC7_P0N%M)BK&3A1-]]?971HIRL&+2J7,?O6_>=7]7@?_GV:P 1D,R,U Q;YG
M0 <#^MO OVO@#P:^K4$P& 2V!N%@$-IJ8(,!TR)X?76[Z=IF,ELO:W%UZG[%
MG;-V8>,%4PMBUPYV\]_]3\U8HT8_UH3Y2^^C=30PFYXA(R9"4R0Q$7PC/)7
M+0L"9;$AACDETP@O)D*":,IL32;"4^05<,,T)GF<37HWTD0P!
85&EK97##!0!:':LH3*&YG%+$S!>W,0J/2PXQ;0_'W
MN;$DW*8H8E,*VA0"1
8+X&4C2$P:Y= 16\#80.ENF5T>1OM?>8+M]^YO+L( .)Q=1S 2Q89=]0*NI$OSO6U_6NWBFV[A2-3B%*].[E?DRW>K"P8,\ZU2&U
M+=)T*<#8\Y[
'W)>U7W,-WXH!E[#*4
M/2[!:)1;END6V6I.;!_O^*HATN7=0M9@1-+-!SR)$@;8%3[G1OW$2/+A24('
M @19]^ $'/!$@1CP1)"P!Q15(73-Q>6M6@Z=>% EH?5)
+N G8F9K:/':V3CQE5/
MIJ(Q7?? BSDUM+;=2=NE2F.44J:SP_A@?, '.0&N=GP\%G(#OTS'8R8W8V Z
M1[.9)3
Related Party Transactions (Details) - USD ($) |
3 Months Ended | 6 Months Ended | 12 Months Ended | |||
---|---|---|---|---|---|---|
Sep. 30, 2017 |
Dec. 31, 2019 |
Dec. 31, 2018 |
Jun. 30, 2019 |
Sep. 30, 2019 |
Feb. 14, 2018 |
|
Related Party Transaction [Line Items] | ||||||
Related Party Transaction, Amounts of Transaction | $ 645,000 | |||||
Related Party Transaction, Rate | 1.25% | |||||
accrued interest related party | $ 112,389 | |||||
Related Party Transaction, Due from (to) Related Party | $ 645,000 | |||||
Preferred Stock, Shares Issued | 2,000,000 | 2,000,000 | 2,000,000 | |||
Common Stock, Voting Rights | 0.7781 | |||||
Convertible Preferred Stock, Shares Issued upon Conversion | 2.15 | |||||
Common Stock, Conversion Basis | 4300000 | |||||
Equity Method Investment, Ownership Percentage | 36.70% | |||||
Dividends Payable, Date to be Paid | $ 96,980 | $ 70,968 | ||||
Dividends Payable, Amount Per Share | $ (0.0428) | $ (0.04) | $ (0.03) |
Retirement and post retirement plans (Details) - USD ($) |
6 Months Ended | ||
---|---|---|---|
Dec. 31, 2019 |
Dec. 31, 2018 |
Jun. 30, 2019 |
|
Accrued expenses [Abstract] | |||
Payment for Pension and Other Postretirement Benefits | $ 8,491 | ||
Liability, Retirement and Postemployment Benefits | $ 791,985 | ||
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate | 4.50% | ||
Other Income | $ 758,000 | ||
Current portion of post-retirement benefits (related party) | $ 0 | $ 101,891 |
Leases (Policies) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases 842 [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases of Lessee Disclosure [Text Block] |
The Company adopted ASC Topic 842-Leases as of July 1, 2019, using the cumulative effective adjustment method wherein the Company applied the new lease standard at adoption date. Accordingly, all periods prior to July 1, 2019 were presented in accordance with the previous ASC Topic 840, Leases, and no retrospective adjustments were made to the comparative periods presented. Adoption of ASC 842 resulted in an increase to total assets and liabilities due to the recording of operating lease ROU and operating lease liabilities of approximately $1,138,000 and $1,208,000 respectively, as of July 1, 2019. The adoption did not materially impact the Company's unaudited condensed consolidated statements of operations or cash flows. The Company determines if a contract contains a lease at inception. US GAAP requires that the Company's leases be evaluated and classified as operating or finance leases for financial reporting purposes. The classification evaluation begins at the commencement date and the lease term used in the evaluation includes the non-cancellable period for which the Company has the right to use the underlying asset, together with renewal option periods when the exercise of the renewal option is reasonable certain and failure to exercise such option which result in an economic penalty. The Company has operating leases for manufacturing, research and corporate office facilities and certain equipment. Leases with an initial term of 12 months or less are not recorded in the balance sheet. The Company has elected the practical expedient to account for each separate lease component of a contract and its associated non-lease components as a single lease component, thus causing all fixed payments to be capitalized. The Company also elected the package of practical expedients permitted within the new standard, which among other things, allows the Company to carry forward historical lease classification. Variable lease payment amounts that cannot be determined at the commencement of the lease such as increases in lease payments based on changes in index rates or usage, are not included in the ROU assets or liabilities. These are expensed as incurred and recorded as variable lease expense. ROU assets represent the Company's right to use an underlying asset during the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at commencement date based on the net present value of fixed lease payments over the lease term. The Company's lease term includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. As the Company's operating leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the comment date in determining the present value of future lease payments. The components of lease costs included in cost of goods sold and marketing, general and administrative costs were as follows:
Supplemental cash flow information was as follows:
Leases recorded on the balance sheet consist of the following:
The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the unaudited condensed consolidated balance sheets as of December 31, 2019: The aggregate future lease payments for operating leases as of December 31, 2019 were as follows:
Average lease terms and discount rates were as follows:
As of December 31, 2019, the Company has an additional operating lease for its Pennsylvania headquarters location that has not yet commenced with a present value of approximately $285,000. The relocation date is January 1, 2020. The operating lease commenced in the third quarter of fiscal year 2020 with a lease term of 5 years. Disclosures related to periods prior to adoption of ASU 2016-02 The Company adopted ASU 2016-02 using a modified retrospective adoption method at July 1, 2019 as noted in note 3. As required, the following disclosure is provided for periods prior to adoption. Minimum operating lease commitments as of June 30, 2019 that have initial or remaining lease terms in excess of one year are as follows:
The rent expense for the three months ended December 31, 2018 was approximately $114,000. |
Line of credit (Notes) |
6 Months Ended |
---|---|
Dec. 31, 2019 | |
Line of Credit Facility [Line Items] | |
Debt Disclosure [Text Block] | Line of Credit On June 29, 2018 the Company entered a business loan agreement with TD bank receiving a line of credit evidenced by a promissory note of $250,000. The interest is subject to change based on changes in an independent index which the Wall Street Journal Prime. The index rate at the date of the agreement is 5.000% per annum. Interest on the unpaid principal balance of the note is calculated using a rate of 0.740 percentage points over the index, adjusted if necessary for any minimum and maximum rate limitations, resulting in an initial rate of 5.740% per annum based on a year of 360 days. The interest rate was 6.24% as of December 31, 2019. The Company was required to put $250,000 in the TD bank savings account as collateral. Mr. Richard J. DePiano Sr. executed a guarantee of the loan in favor of TD Bank. Mr. DePiano Sr. passed away on October 3, 2019, therefore the guarantee is now assumed by his estate. Upon signing the agreement the Company also authorizes TD bank to payoff the line of credit with Newtek Business Credit ("Netwtek"). The total payment was $201,575 which includes $165,000 of outstanding line of credit, $2,579 accrued interest, administrative/legal fee of $1,000, prime plus fee through July 12, 2018 of $1,895 and fees of $28,797. The line of credit from Newtek was paid off on July 3, 2018. As of December 31, 2019 and June 30, 2019, the line of credit balance was $201,575 with TD bank. The line of credit interest expense was approximately $4,000 and $3,000 for the three months ended December 31, 2019 and 2018, respectively. The line of credit interest expense was approximately $8,000 and $10,000 for the six-month periods ended December 31, 2019 and 2018, respectively. |
Significant Accounting Policies (Inventory) (Details) - USD ($) |
Dec. 31, 2019 |
Jun. 30, 2019 |
---|---|---|
schedule of inventory [Abstract] | ||
Inventory, Raw Materials, Net of Reserves | $ 887,000 | $ 875,000 |
Inventory, Work in Process, Net of Reserves | 183,000 | 225,000 |
Inventory, Finished Goods, Net of Reserves | 894,000 | 779,000 |
Inventory, net | $ 1,963,845 | $ 1,878,860 |
Inventories (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Inventory, Current [Table Text Block] |
|
Significant Accounting Policies Goodwill and intangible assets (Details) - USD ($) |
6 Months Ended | |
---|---|---|
Dec. 31, 2019 |
Dec. 31, 2018 |
|
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Impairment of Intangible Assets (Excluding Goodwill) | $ 605,005 | $ 0 |
Label | Element | Value |
---|---|---|
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | $ 1,124,002 |
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | 662,878 |
Cash | us-gaap_Cash | 1,124,002 |
Cash | us-gaap_Cash | $ 662,878 |
JYG7])S7]2IN IN'(O'OLS<^IVMO@OJOW+M/6[J?:7_9R'W,<[B+*W3[[J
MVM[#G=TBVA?-]XQBV9 V%" B>*5 WTS$<."?Q.W(DS%Z<,TCC&0@$;C;@' [MGIZ/3LK-OI33J#
MT>GEJ=,][7<[9Q>7EX->]VQ:>0#PJ7-^'WU*:3>HLQ9VQK^+KPFC>, ><(9PAG#F4/:,O;X.=5]Y
MPAG"&<*9 ^',N$LX4V78Z[BB6U,8F"HJI3"T_3#TT9W]UA_0T:$D#R0/JST6
M:T8]R0/)0^/E83@F>2!Y('E8V4O6TCN.11XHU>!QVIJ"3_9-N-%-"+]1ID&=
MX.=X:DBN44]H2[$=(,":CD=(R&X'EX)FG
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M#.$+1V/=T$5:<&GN3ZQKJ!Y"%;DHBHH%]:U5Z!LD000CCDK>2@?),
MRUQLT[)9C!@7^\EL"N)R@Y-58[&:Q[U<<$*GR-&3D90\XUSQ#(580S92*F^;
MO8S)4B^I^@X@-H!SESLC.B#=K+2>RN@G:1W'L$L78=&M89+WG?OW0W$/>%?I
MNUS#D)6L!?I@'%F :AL(YP4W&>THQ@?-6^/ &;2)^@& [KRP@&H(4(AXXBE!
M 21V\,C'U+55&-13!P=ZQRN*]5D>&BA.152<1Q?-FZR]]0D]-1'Z3F76 G(_
MJ'M91#-O@/F8BP((DEI,RH"6U&!0*4W#'-3U!N1#@M[=Q(S,%Q.\**K0C(3.
MGBFCBM)6"MM,\-PCZ.^&'\]F;T[_.9V7&MR*3P)0-(JN6$3NIIS'$+(K"D-6
MXW$-^K*A>H'8'=H^_M!9<;0?LF1.WECT,65D9HR00A!*-WQQ9X10;5[8WD'N
MY O%L]=!1L&I,['++DE!1>@%.A59-6N\/P#(:XA,92BDCW3XAD3FV66*ZQ6C
M=H\AM]0AP;C?FC93O1W(_ZIH9'7B/^&O'ZOZZM[5J+[]=-WGP^#$$.$X5PF;XO8P2
M^!-^!!S.,;R@ @"$W'5F=O5RQ+ <+:TC9,*6L0\O6:H'X36/(5PK5PK"6UT%
M3_<$_)*=P U N"%#A==J_0 /6AJ=LW$_\R6[T
^N_BT,(H
M7O"@!)%=O"8?GF9,5P2!N>;/'SH?U-\ @F[V]Y;Q?_<7P)L_BSOV+5KP#:/G
MSO>2^>?)N-USQOWN<-)U^N/1J/M#!L6 L@%?2O$Y^_!E'5E70RQNHZS0V=EJ
MEKU\)T:/T!G]\#S^;]5?^O[NOO]G8:_>%N'[SIZQNR+UD[7RH?[N"P#3==
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M9ZP4*S5"L)]S:-/>X.;&IL$FX2;A+N>@@W:6X2;A+N(Q5NTMP'<^$?[[6P
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MUN;'; 8KQ6YQJ=BU<'DJ!8MFYC =)F;]@
M#!&, .M]>:C&LFV8R-7%4"Y>!W*FQE66CTGV9@<
M* (SM^+S0P5T*ES\$7_^Q.X$#F&!0A9CP'EF2I0350^OV_#X]R<+6(4YAIC]
MR)-,;!0M,RR.4E=C/4I[LWG+,\*TJVP4!>P_H\B[\X, [O@Q3Y,+EGJC#K
M]1)UZO0'_=.SRTY_>#'H32ZFP_,+Y_)L=#D\.^U?GO>.3*)R>F4@[PG0M@JM
M58
7IE5YS5TC8UQ@H8RH/KHU4]]R7<[+N*IT)P)OVE
MT@:><''UU!1BG)AF.P/J\'BPT<"0Q>]R^.4>C!"T4&'V.,/K5.*3)'ALF;G-
MDQTH<2T,U5&+_ .(7ER$ AUPK9:@B.#KEE%*AG;*!"X9A*AK%V#^I9A >8U^
MPR5L#PM"6)?%(T\CR00L^7ROE %DG!21 KBH/:N5\*Y;S C3"3&^"96-T'
M;\V?"DNKWP'4_4U?7GILX7E*U:^&@Y,.D,BYRGYR\,7Y9R9O/K85E=%6*1!9
M_XSDO FU35JFWLJ*Q;_NYCZ8_$_X%'H$8*X(X6F3I^ U%*]I#.(4G2LP_!7B
M9+H'D&@F'D%:"<*+\4Y_\^43:$6HRD
M&'C6AI1<19J!